Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Genmab A/S - ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
GMAB
Nasdaq
8731
https://www.genmab.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Genmab A/S - ADR
Transactions in Connection with Share Buy-back Program
- Mar 25th, 2024 1:31 pm
Completion of share buy-back program
- Mar 18th, 2024 9:49 am
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Genmab Announces Initiation of Share Buy-Back Program
- Mar 15th, 2024 12:16 pm
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Mar 13th, 2024 8:58 pm
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
- Mar 13th, 2024 8:53 pm
Passing of Genmab A/S’ Annual General Meeting
- Mar 13th, 2024 3:13 pm
Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Feb 27th, 2024 8:40 pm
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
- Feb 27th, 2024 12:45 pm
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
- Feb 23rd, 2024 10:35 pm
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript
- Feb 15th, 2024 3:47 pm
Genmab: Growth Is Still a Better Choice
- Feb 15th, 2024 1:00 pm
Notice to Convene the Annual General Meeting of Genmab A/S
- Feb 15th, 2024 11:00 am
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
- Feb 14th, 2024 7:09 pm
Genmab Publishes 2023 Annual Report
- Feb 14th, 2024 4:02 pm
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
- Feb 2nd, 2024 11:45 am
Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Jan 25th, 2024 7:22 pm
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
- Jan 23rd, 2024 11:24 am
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
- Jan 22nd, 2024 11:40 pm
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Jan 19th, 2024 2:55 pm
Scroll